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Introduction 
Outcome and prognosis of patients suffering from 
6-pyruvoyl tetrahydropterin synthase (PTPS) defi-
ciency are strictly dependent on the control of hy-
perphenylalaninemia and biogenic amine deficien-
cy. While the former can be easily normalized by 
a phenylalanine restricted diet or by synthetic te-
trahydrobiopterin (BH.) administration, adequate 
dopamine and serotonin supply is hampered by a 
number of drawbacks. Only a few patients respond 
to BH4 monotherapy by increasing their mono-
amine production at the central level, while most 
patiemts have to be given neurotransmitter substi-
tutive therapy, individually adjusted as for the daily 
dose and the number of administrations (1). Ran-
dom fluctuations in motor and cognitive performan-
ces may appear in patients on neurotransmitter 
therapy, especially when larger doses of I-Dopa are 
required, owing to interference of neurotransmitter 
precursor and phenylalanine metabolism (2) or to 
plasma dopamine fluctuations related to the short 
I-Dopa half-life (3). 
Recently, we pointed out in two patients with 
unsatisfactory response to a classical treatment that 
therapeutic inadequacy was corrected by the con-
current administration of I-Deprenyl (selegiline, 
phenylisopropylmethylpropynilamine), a selective, 
irreversible inhibitor of monoamine oxidase B (4). 
Three additional patients with PTPS deficieny were 
subsequently treased and results are here reported. 
§ Author to whom correspondence should be addressed. 
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Patient Selection and Treatment 
Five patients suffering from different forms of 
PTPS deficiency were included in this study. Four 
of them were followed in Torino and one in Bu-
dapest. A definite diagnosis was obtained by the 
analysis of urinary pterins, the measurement of en-
zyme activity in red biood cells, and by a BH4 
loading test. CSF levels of homovanillic acid (HV A) 
and of 5-hydroxyndole acetic acid (5-HIAA) were 
measured before and after therapy. As shown in 
Table 1, four patiens (cases 1-4) belonged to the 
classical type of the disease, while the fifth was af-
fected by a partial PTPS deficiency. All patients but 
one (case 5, T.G.) had been treated following the 
current approach with BH4, I-Dopa, 5-0H-Trp plus 
carbidopa (1:10 to I-Dopa) at the doses reported in 
Tabe 2. Cases 1 and 2 were poorly responsive to the 
therapy, cases 3 and 4 were good responders, though 
erratic symptoms of biogenic amine deficiency reap-
peared, generally late in the afternoon (Table 2). 
Case 5 had been treated for the first three years of 
life with cofactor therapy alone (2.4 to 4.9 mg/kg 
body weight per day) because of persistent hyper-
phenylalaninemia with normal CSF neurotransmi-
tter metabolites. Afterwards, this "peripheral" phe-
notype reverted to a "central" phenotype, with no-
rmal serum phenylalnine on free diet, and progres-
sive reduction of CSF biopterin, HV A, and 5-HIAA 
concentrations (5). However, this girl had always 
been symptom free , with normal physical, intelle-
ctual and motor development. All patients were gi-
ven I-Deprenyl at the dose of 0.25 mg/kg body 
weight per day, in a single oral administration, in 
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Table 1. Clinical and biochemical data of five PTPS defi-
cient patients enrolled in treatment with 1-Depreny1 
CSF neurotransmitter metabolite 
Clincal lenls (nmol/L)* 
Patients phenotype Age on classical at diagnosis 
treatment 
HVA 5-HIAA HVA 5-HIAA 
1. M.T. classic 4.5 yr 421 163 
2. I.A. classic 9 yr 34 13 288 162 
3. Y.P. classic 8.5 yr 70 21 283 202 
4. G .P. classic 12.5 yr 91 IS 349 120 
5. T.G. partial 10.5 yr 610 300 220 31 
*Control values: HVA= 250-880; 5-HIAA= 110-360 
addition to the classical treatment. At the beginning 
of the trial neurotransmitter therapy was progres-
sively reduced, and adjusted by clinical monitoring 
to obtain the maximal efficacy with the lowest pre-
cursor dose. Patients age at the onset of the trial 
ranged 5 months to 11.5 years, the interval between 
diagnosis and 1-Deprenyl administration ranged 4 
months to II years and the duration of this medi-
cation ranged 7 months to 4 years (Table 2). 
Results and Discussion 
I-Deprenyl is a monoamine oxidase B-type inhi-
bitor, relatively devoid of pressor effect in man (6), 
which is currently under evaluation in the treatment 
of Parkinson's disease (7,8). The scientific rationale 
of this therapy in BH4 deficiency arises from its 
ability to increase the concentration of dopamine 
and serotonin in the brain by limiting the degra-
dation of both neurotransmitters (9). Additional ef-
fects of potential advantage have been demonstra-
ted. I-Deprenyl can be metabolized to amphetam-
ines, which enhance the re-uptake of dopamine. 
with antidepressant and anticholinergic effects ( 10) 
It also promotes the accumulation of phenylethyl-
amine, which potentiates the action of dopamine 
(11), and displays a protective activity against dif-
ferent neurotoxins (12, 13). 
The preliminary results here reported stongly in-
dicate the beneficial effect of I-Deprenyl in PTPS 
deficiency, as its administration allowed: 
a) to treat a patient otherwise unresponsive to 
neurotransmitter therapy, 
b) to relieve symptoms residual to neurotransmit-
ter therapy in three patients 
c) to reduce by 20 to 40% the previous dosage of 
neurotransmitter precursors; 
d) to reduce in a patient the number of daily 
administrations of neurotransmitter precursors; 
e) to stabilize the clinical response, avoiding the 
appearance of erratic symptoms of biogenic amine 
deficiency, or on-off phenomena. 
As for the patient affected by partial PTPS de-
ficiency, I-Deprenyl therapy was tentatively intro-
duced with the aim of correcting the progressive 
amine deficiency without neurotransmitter precur-
sor administration. At present, however, as the pa-
tient is permanently asymptomatic it is not possible 
to evaluate possible benefits on a clinical basis. 
No adverse effect, such as cardiac arrhythmia 
(14) or increased serum aspartate and alanine ami-
notransferase levels (15, 16), was observed with the 
dosage of I-Deprenyl employed in our trial.Long 
term treatment will clarify whether the effect of 1-
Deprenyl is merely symptonatic, as suggested by our 
preliminary results, or whether other mechanism(s) 
contribute to improve the outcome and prognosis 
of patients suffering from BH4 deficiency. 
Table 2. Treatment with I-Deprenyl in five PTPS deficient patients 
Age at onset Treatment before and after 
Cinical picture 
Patients 
I-Deprenyl adminstration 
of I-Deprenyl therapy mg/kg per day (daily administrations) 
I-Deprenyl BH4 I-Dopa 50H-Trp 
I . M.T. 5 mo 5.5(1 ) 5.2(3) 5.9(3) unresponsive. myoclonic convulsions 
0.25 6.6(1) 3.6(3) 4.8(3) 
2. LA. 7 yr 8( 1) 12(8) 9(8) on-off phenomena, dystonia 
0.25 8(1) 8(3) 5(3) 
3. Y.P. 7.5 yr 5(1) 6.3(3) 5.4(3) end of dose symptons, diurnal clinical 
fluctuations 
0.25 5(1) 5(3) 4(3) 
4. G.M. J 1.5 yr 4.5(1) 6(3 ) 5(3) wearing off symptons, depression 
O.::!5 4.5(1 ) 4.1(3) 3(3) 
5. T.G. j(1 \T symptom free 
Cl25 
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